|
Intellectual Disability
|
0.310 |
GeneticVariation
|
group |
BEFREE |
Thus, ACTL6A gene mutation analysis should be considered in patients with intellectual disability, learning disabilities, or developmental language disorder.
|
28649782 |
2017 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Mechanistically, ACTL6A promotes metastasis and EMT through activating Notch signaling.
|
26698646 |
2016 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
ACTL6A-overexpression and ACTL6A-knockdown colon cancer cells were used to perform cytological experiments to explore the potential biological function of ACTL6A in metastasis and EMT in colon cancer.
|
30348114 |
2018 |
|
Neoplasm Metastasis
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
Both in vitro and in vivo assays showed that ACTL6A overexpression promoted osteosarcoma cell invasion and metastasis, whereas knockdown of ACTL6A expression reduced osteosarcoma cell malignant behavior such as invasion and metastasis.
|
28260090 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Further functional analysis indicated that BAF53a overexpression could promote proliferation and increase the motility and invasion of U87 glioma cells, whereas BAF53a knockdown had the opposite effect.
|
29039584 |
2017 |
|
Tumor Cell Invasion
|
0.030 |
AlteredExpression
|
phenotype |
BEFREE |
ACTL6A overexpression promoted migration and invasion of colon cancer cells, whereas ACTL6A knockdown exhibited the opposite effect in vitro.
|
30348114 |
2018 |
|
Malignant Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The data from both the Gene Expression Omnibus (GEO) and Oncomine databases showed that ACTL6A expression levels in colon adenoma and cancer were higher than those in normal colon samples.
|
30348114 |
2018 |
|
Malignant Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
ACTL6A promotes malignant behaviors of glioma cells in vitro and in orthotopic xenograft model.
|
29725063 |
2018 |
|
Glioma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Therefore, BAF53a could be a potential promising biomarker and a target for the treatment of glioma.
|
29039584 |
2017 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
These results indicate that failure to downregulate the BAF53a subunit may contribute to the pathogenesis of RMS, and suggest that BAF53a may represent a novel therapeutic target for this tumor.
|
23728344 |
2014 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Immunohistochemical analyses of osteosarcoma tissue samples from two independent cohorts of formaldehyde-fixed, paraffin-embedded osteosarcoma tissue samples from total of 186 osteosarcoma patients showed that high ACTL6A expression correlated with malignant clinicopathological features such as larger tumor size, high Ennecking grade, high histologic grade, and advanced tumor node metastasis stage.
|
28260090 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Increasing evidence indicates that BAF53a is crucial for embryonic development and maintenance of stemness, and may be associated with epithelial-mesenchymal transition (EMT), which suggests its involvement in cancer progression.
|
29039584 |
2017 |
|
Tumor Progression
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that ACTL6A may contribute to cancer progression by stabilizing YAP/TAZ and therefore provide a novel therapeutic target for the treatment of human gliomas.
|
29725063 |
2018 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Increased Actin-like 6A (ACTL6A) expression has been implicated in the development of diverse cancers and recently associated with the Hippo signaling pathway, which is known to regulate biological properties, including proliferation, tissue regeneration, stem cell biology, as well as tumorigenesis.
|
29725063 |
2018 |
|
Carcinogenesis
|
0.020 |
AlteredExpression
|
phenotype |
BEFREE |
Ectopic ACTL6A/p63 expression promotes tumorigenesis, while ACTL6A expression and YAP activation are highly correlated in primary HNSCC and predict poor patient survival.
|
28041841 |
2017 |
|
Primary malignant neoplasm
|
0.020 |
Biomarker
|
group |
BEFREE |
However, the roles of ACTL6A in the development of ovarian cancer and the regulation of cancer glucose metabolism are mostly unknown.
|
31649264 |
2019 |
|
Primary malignant neoplasm
|
0.020 |
AlteredExpression
|
group |
BEFREE |
The data from both the Gene Expression Omnibus (GEO) and Oncomine databases showed that ACTL6A expression levels in colon adenoma and cancer were higher than those in normal colon samples.
|
30348114 |
2018 |
|
Liver carcinoma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
A high level of ACTL6A in HCCs is correlated with aggressive clinicopathological features and is an independent poor prognostic factor for overall and disease-free survival of HCC patients.
|
26698646 |
2016 |
|
Liver carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Actin-like 6A (ACTL6A) is vital for embryogenesis and differentiation and is also critical for metastasis and EMT in hepatocellular carcinoma, as observed in our previous study.
|
30348114 |
2018 |
|
Malignant tumor of colon
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The ACTL6A expression level in fresh colon cancer specimens was also higher than that in the corresponding adjacent normal colon specimens.
|
30348114 |
2018 |
|
Squamous cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
ACTL6A Is Co-Amplified with p63 in Squamous Cell Carcinoma to Drive YAP Activation, Regenerative Proliferation, and Poor Prognosis.
|
28041841 |
2017 |
|
Acute Promyelocytic Leukemia
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To identify the genes that may participate in the development of APL, we analyzed data from an APL cDNA microarray (GSE12662) in the NCBI database, and found that ACTL6A was up-regulated in APL patients.
|
30448346 |
2019 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, data from the present study demonstrated that ACTL6A was associated with poor survival and promoted osteosarcoma cell metastasis through EMT, suggesting that ACTL6A may be a novel prognostic biomarker and therapeutic target for osteosarcoma.
|
28260090 |
2017 |